Tags

Type your tag names separated by a space and hit enter

Comparison of azithromycin versus clarithromycin in the treatment of patients with lower respiratory tract infection.
J Antimicrob Chemother. 1993 Jun; 31 Suppl E:153-62.JA

Abstract

The efficacy and safety of azithromycin and clarithromycin in lower respiratory tract infection (LRTI) were compared in an open, multicentre study. Five hundred and ten adult patients with a diagnosis of LRTI, including acute bronchitis, acute infective exacerbations of chronic bronchitis (AIECB) or pneumonia were enrolled. The patients were randomly assigned to receive either azithromycin (n = 252) as a single daily dose of 500 mg for three days, or clarithromycin (n = 258) 250 mg twice daily for ten days. In AIECB patients, baseline comparisons of the two treatment groups showed that there were no differences in the number of previous episodes of infection or in the incidence of current or past smokers. The overall clinical efficacy was found to be similar in each treatment group on day 10 to 14, with a satisfactory response (cured or improved) in 94% of azithromycin- and 97% of clarithromycin-treated patients. At follow-up evaluation (day 18 to 22), 97% of azithromycin- and 100% of clarithromycin-treated patients who had improved at day 10 to 14, showed satisfactory outcomes. Bacteriological efficacy was similar in both treatment groups, with eradication of 100% vs 95% of isolates in the azithromycin and clarithromycin groups, respectively. In AIECB, 100% of pathogens were eradicated by azithromycin, although one patient was clinically assessed as failed. Clarithromycin eradicated 93% of pathogens in this group; all patients being assessed as cured or improved. Both drugs were well tolerated, with 9% and 6% of patients reporting adverse events with azithromycin and clarithromycin, respectively. These adverse events were largely gastrointestinal in origin. It was concluded that a three-day course of azithromycin is as effective and well tolerated as a ten-day course of clarithromycin in adults with acute LRTIs.

Authors+Show Affiliations

ICON Clinical Research Ltd, Dublin, Ireland.

Pub Type(s)

Clinical Trial
Comparative Study
Journal Article
Multicenter Study
Randomized Controlled Trial

Language

eng

PubMed ID

8396087

Citation

Bradbury, F. "Comparison of Azithromycin Versus Clarithromycin in the Treatment of Patients With Lower Respiratory Tract Infection." The Journal of Antimicrobial Chemotherapy, vol. 31 Suppl E, 1993, pp. 153-62.
Bradbury F. Comparison of azithromycin versus clarithromycin in the treatment of patients with lower respiratory tract infection. J Antimicrob Chemother. 1993;31 Suppl E:153-62.
Bradbury, F. (1993). Comparison of azithromycin versus clarithromycin in the treatment of patients with lower respiratory tract infection. The Journal of Antimicrobial Chemotherapy, 31 Suppl E, 153-62.
Bradbury F. Comparison of Azithromycin Versus Clarithromycin in the Treatment of Patients With Lower Respiratory Tract Infection. J Antimicrob Chemother. 1993;31 Suppl E:153-62. PubMed PMID: 8396087.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Comparison of azithromycin versus clarithromycin in the treatment of patients with lower respiratory tract infection. A1 - Bradbury,F, PY - 1993/6/1/pubmed PY - 1993/6/1/medline PY - 1993/6/1/entrez SP - 153 EP - 62 JF - The Journal of antimicrobial chemotherapy JO - J Antimicrob Chemother VL - 31 Suppl E N2 - The efficacy and safety of azithromycin and clarithromycin in lower respiratory tract infection (LRTI) were compared in an open, multicentre study. Five hundred and ten adult patients with a diagnosis of LRTI, including acute bronchitis, acute infective exacerbations of chronic bronchitis (AIECB) or pneumonia were enrolled. The patients were randomly assigned to receive either azithromycin (n = 252) as a single daily dose of 500 mg for three days, or clarithromycin (n = 258) 250 mg twice daily for ten days. In AIECB patients, baseline comparisons of the two treatment groups showed that there were no differences in the number of previous episodes of infection or in the incidence of current or past smokers. The overall clinical efficacy was found to be similar in each treatment group on day 10 to 14, with a satisfactory response (cured or improved) in 94% of azithromycin- and 97% of clarithromycin-treated patients. At follow-up evaluation (day 18 to 22), 97% of azithromycin- and 100% of clarithromycin-treated patients who had improved at day 10 to 14, showed satisfactory outcomes. Bacteriological efficacy was similar in both treatment groups, with eradication of 100% vs 95% of isolates in the azithromycin and clarithromycin groups, respectively. In AIECB, 100% of pathogens were eradicated by azithromycin, although one patient was clinically assessed as failed. Clarithromycin eradicated 93% of pathogens in this group; all patients being assessed as cured or improved. Both drugs were well tolerated, with 9% and 6% of patients reporting adverse events with azithromycin and clarithromycin, respectively. These adverse events were largely gastrointestinal in origin. It was concluded that a three-day course of azithromycin is as effective and well tolerated as a ten-day course of clarithromycin in adults with acute LRTIs. SN - 0305-7453 UR - https://www.unboundmedicine.com/medline/citation/8396087/Comparison_of_azithromycin_versus_clarithromycin_in_the_treatment_of_patients_with_lower_respiratory_tract_infection_ L2 - https://academic.oup.com/jac/article-lookup/doi/10.1093/jac/31.suppl_e.153 DB - PRIME DP - Unbound Medicine ER -